These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 15215115

  • 1. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
    MacGowan AP, Noel AR, Rogers CA, Bowker KE.
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
    [Abstract] [Full Text] [Related]

  • 2. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Berry V, Thorburn CE, Knott SJ, Woodnutt G.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
    [Abstract] [Full Text] [Related]

  • 3. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
    Berry V, Hoover J, Singley C, Woodnutt G.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
    [Abstract] [Full Text] [Related]

  • 4. Elements of design: the knowledge on which we build.
    MacGowan AP.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
    [Abstract] [Full Text] [Related]

  • 5. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
    [Abstract] [Full Text] [Related]

  • 6. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM, Prause JL, Danziger LH, Pendland SL.
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [Abstract] [Full Text] [Related]

  • 7. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
    Pottumarthy S, Sader HS, Fritsche TR, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic studies of amoxicillin against Streptococcus pneumoniae: comparison of a new pharmacokinetically enhanced formulation (2000 mg twice daily) with standard dosage regimens.
    Odenholt I, Cars O, Löwdin E.
    J Antimicrob Chemother; 2004 Dec; 54(6):1062-6. PubMed ID: 15563517
    [Abstract] [Full Text] [Related]

  • 9. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM, Jacobs MR, Good CE, Bajaksouzian S, Windau A, Jakielaszek C, Saunders KA.
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation.
    Löwdin E, Cars O, Odenholt I.
    Clin Microbiol Infect; 2002 Oct; 8(10):646-53. PubMed ID: 12390283
    [Abstract] [Full Text] [Related]

  • 11. Proof of concept: performance testing in models.
    Craig WA.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():12-7. PubMed ID: 14759229
    [Abstract] [Full Text] [Related]

  • 12. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.
    Andes D, Craig WA.
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2375-9. PubMed ID: 9736566
    [Abstract] [Full Text] [Related]

  • 13. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
    Hoberman A, Dagan R, Leibovitz E, Rosenblut A, Johnson CE, Huff A, Bandekar R, Wynne B.
    Pediatr Infect Dis J; 2005 Jun; 24(6):525-32. PubMed ID: 15933563
    [Abstract] [Full Text] [Related]

  • 14. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B.
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
    Woodnutt G, Berry V.
    Antimicrob Agents Chemother; 1999 Jan; 43(1):35-40. PubMed ID: 9869562
    [Abstract] [Full Text] [Related]

  • 16. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
    Jacobs MR.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
    [Abstract] [Full Text] [Related]

  • 17. Performance in practice: bacteriological efficacy in patients with drug-resistant S. pneumoniae.
    Garau J.
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():28-35. PubMed ID: 14759231
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM, Garau J, Jacobs MR, Wynne B, Twynholm M, Berkowitz E.
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics of gemifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model of infection.
    MacGowan AP, Rogers CA, Holt HA, Wootton M, Bowker KE.
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2916-21. PubMed ID: 11557490
    [Abstract] [Full Text] [Related]

  • 20. Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model.
    Soriano F, Parra A, Cenjor C, Nieto E, García-Calvo G, Giménez MJ, Aguilar L, Ponte C.
    J Infect Dis; 2000 Feb; 181(2):646-52. PubMed ID: 10669350
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.